VSVigdis Stefansdottir

Vigdis Stefansdottir

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Vigdis Stefansdottir has a total of 358 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Meeting the demand: A collaborative approach in developing genetic counselling education in the Nordic countries

    by Elen Siglen, Essi Ylistalo, Åshild Lunde, Arnhildur Tomasdottir, Marianne Lodahl, Charlotta Ingvoldstad Malmgren, Hakon Bjørn Hognason, Eirny T Thorolfsdottir, Mari Laaksonen, Vigdis Fjola Stefansdottir, et al.

    This program report describes the establishment of the Nordic Network for Genetic Counselling (NNGC) and the ongoing work toward developing a joint Nordic MSc in Genetic Counselling and increasing awareness of genetic counselling in the Nordic countries. Founded officially in 2024, the NNGC brings together universities and university hospitals across the Nordic region and draws on members varied clinical and academic backgrounds. With financial support from NordPlus, the network has built a collaborative framework based on shared responsibility, rotating coordination, and regular digital and in-person meetings. Using the previously EBMG accredited Swedish MSc as a point of reference, the network has a curriculum that aligns with international standards and Nordic priorities related to sustainability, equity, and educational quality. Formal agreements between participating institutions have secured engagement and provided a basis for the development of the master’s programme. The learning points from this collaborative work, including key facilitators, identified barriers, and recommendations when pursuing similar initiatives are presented. Although still under development, the planned Nordic MSc, expected to launch in 2027, demonstrates how regional/international collaboration can strengthen specialized education and support the future workforce needs of precision medicine.

  • Open Access

    Cascade counselling and testing. Recommendations of the European Society of Human Genetics

    by Guido de Wert, Carla G. van El, Angus Clarke, Christophe Cordier, Florence Fellmann, Maurizio Genuardi, Sabine Hentze, Hülya Kayserili, Milan Macek, Rhona MacLeod, et al.

    Cascade testing (CT) is an effective instrument for identifying an index patient’s relatives at high risk of a heritable condition enabling informed decision-making on preventive interventions and reproductive choice. However, CT remains underutilised and faces barriers. Discussions are ongoing on how to optimise informing family members and testing uptake in a responsible manner. The European Society of Human Genetics (ESHG) contributes to this debate and provides recommendations based on an ethical analysis of when CT is justified, or may be less compelling, considering proportionality and the judicious use of finite resources. ESHG underscores the strong consensus regarding the ‘moral architecture’ of CT in cases of a high risk of serious, avoidable harm. In such cases, a more active approach towards CT is suggested, including a more directive approach in counselling, more active support for the proband, direct contacting, and balancing confidentiality when this is necessary to avoid a high risk of serious harm, taking account of national regulations and jurisdictions. In contrast, more caution is advised in more complex cases where the balance of benefits and harms of CT is less clear, such as when penetrance is low, and actionability or medical treatment is limited. This more cautious approach does not call for directivity, direct contact or the relaxing of medical confidentiality. The focus, then, shifts to cascade counselling, rather than cascade testing. In some cases, CT may not be proportional or appropriate given the balance between benefits and harms, also in view of available resources.


  • Open Access

    A population-based survey of FBN1 variants in Iceland reveals underdiagnosis of Marfan syndrome

    by Elin Ola Klemenzdottir, Gudny Anna Arnadottir, Brynjar Orn Jensson, Adalbjorg Jonasdottir, Hildigunnur Katrinardottir, Run Fridriksdottir, Aslaug Jonasdottir, Asgeir Sigurdsson, Sigurjon Axel Gudjonsson, Jon Johannes Jonsson, et al.

    Marfan syndrome (MFS) is an autosomal dominant condition characterized by aortic aneurysm, skeletal abnormalities, and lens dislocation, and is caused by variants in the FBN1 gene. To explore causes of MFS and the prevalence of the disease in Iceland we collected information from all living individuals with a clinical diagnosis of MFS in Iceland (n = 32) and performed whole-genome sequencing of those who did not have a confirmed genetic diagnosis (27/32). Moreover, to assess a potential underdiagnosis of MFS in Iceland we attempted a genotype-based approach to identify individuals with MFS. We interrogated deCODE genetics’ database of 35,712 whole-genome sequenced individuals to search for rare sequence variants in FBN1. Overall, we identified 15 pathogenic or likely pathogenic variants in FBN1 in 44 individuals, only 22 of whom were previously diagnosed with MFS. The most common of these variants, NM_000138.4:c.8038 C > T p.(Arg2680Cys), is present in a multi-generational pedigree, and was found to stem from a single forefather born around 1840. The p.(Arg2680Cys) variant associates with a form of MFS that seems to have an enrichment of abdominal aortic aneurysm, suggesting that this may be a particularly common feature of p.(Arg2680Cys)-associated MFS. Based on these combined genetic and clinical data, we show that MFS prevalence in Iceland could be as high as 1/6,600 in Iceland, compared to 1/10,000 based on clinical diagnosis alone, which indicates underdiagnosis of this actionable genetic disorder.


  • Person-Centered Genetic Counselling

    by Vigdis Stefansdottir, Jon J. Jonsson, Christine Patch


  • Open Access

    Correction to: Reply to Letter by Tellier et al., ‘Scientific refutation of ESHG statement on embryo selection’

    by Francesca Forzano, Olga Antonova, Angus Clarke, Guido de Wert, Sabine Hentze, Yalda Jamshidi, Yves Moreau, Markus Perola, Inga Prokopenko, Andrew Read, et al.

  • Open Access

    Reply to Letter by Tellier et al., ‘Scientific refutation of ESHG statement on embryo selection’

    by Francesca Forzano, Olga Antonova, Angus Clarke, Guido de Wert, Sabine Hentze, Yalda Jamshidi, Yves Moreau, Markus Perola, Inga Prokopenko, Andrew Read, et al.


  • Open Access

    A population-based survey of FBN1 variants in Iceland reveals underdiagnosis Marfan syndrome

    by Patrick Sulem, Gudny Arnadottir, Brynjar Jensson, Adalbjorg Jonasdottir, Hildigunnur Katrinardottir, Run Fridriksdottir, Aslaug Jonasdottir, Asgeir Sigurdsson, Sigurjon Gudjonsson, Jon Jonsson, et al.

    Marfan syndrome is an autosomal dominant condition characterized by aortic aneurysm, skeletal abnormalities, and lens dislocation, and is caused by mutations in the FBN1 gene. To explore causes of Marfan syndrome and the prevalence in Iceland we collected samples and information from all living individuals with a clinical diagnosis of Marfan syndrome in Iceland (n = 35) and performed whole-genome sequencing of those who did not have a confirmed genetic diagnosis. Moreover, to assess a potential underdiagnosis of Marfan syndrome in Iceland we attempted a genotype-based approach for identifying individuals with Marfan syndrome. We interrogated deCODE genetics’ database of 35,712 whole-genome sequenced individuals to search for rare sequence variants in FBN1. Overall, we identified 15 pathogenic or likely pathogenic variants in FBN1 in 41 living individuals, only 22 of whom were previously diagnosed with Marfan syndrome. The most common of these variants, NM_000138.4:c.8038C > T (p.Arg2680Cys), is present in a multi-generational pedigree, and was found to stem from a single forefather born around 1840. The p.Arg2680Cys associates with a form of Marfan syndrome that seems to have an enrichment of abdominal aortic aneurysm, suggesting that this may be a particularly common feature of p.Arg2680Cys-associated Marfan syndrome. Based on these combined genetic and clinical data, we estimate a Marfan syndrome prevalence of at least 1/6,000 in Iceland, compared to 1/10,000 based on clinical diagnosis alone, which indicates underdiagnosis of this actionable genetic disorder.

  • Open Access

    Correction: The use of polygenic risk scores in pre-implantation genetic testing: an unproven, unethical practice

    by Francesca Forzano, Olga Antonova, Angus Clarke, Guido de Wert, Sabine Hentze, Yalda Jamshidi, Yves Moreau, Markus Perola, Inga Prokopenko, Andrew Read, et al.

  • Open Access

    Correction: The use of polygenic risk scores in pre-implantation genetic testing: an unproven, unethical practice

    by Francesca Forzano, Olga Antonova, Angus Clarke, Guido de Wert, Sabine Hentze, Yalda Jamshidi, Yves Moreau, Markus Perola, Inga Prokopenko, Andrew Read, et al.


  • Open Access

    The use of polygenic risk scores in pre-implantation genetic testing: an unproven, unethical practice

    by Francesca Forzano, Olga Antonova, Angus Clarke, Guido de Wert, Sabine Hentze, Yalda Jamshidi, Yves Moreau, Markus Perola, Inga Prokopenko, Andrew Read, et al.

    Polygenic risk score analyses on embryos (PGT-P) are being marketed by some private testing companies to parents using in vitro fertilisation as being useful in selecting the embryos that carry the least risk of disease in later life. It appears that at least one child has been born after such a procedure. But the utility of a PRS in this respect is severely limited, and to date, no clinical research has been performed to assess its diagnostic effectiveness in embryos. Patients need to be properly informed on the limitations of this use of PRSs, and a societal debate, focused on what would be considered acceptable with regard to the selection of individual traits, should take place before any further implementation of the technique in this population.